The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
Multiple Myeloma is a type of blood cancer that develops in plasma cells — white blood cells responsible for producing ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
The List on MSN6h
What We Know About Bruce Springsteen's Wife Patti's Health IssuesPatti Scialfa revealed that she has been battling cancer for years. Here's what Bruce Springsteen's wife and bandmate has ...
Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...
Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...
(RTTNews) - Johnson & Johnson (JNJ), Friday announced the submission of regulatory applications for Darzalex Faspro to the U.S. Food and Drug Administration, and Darzalex to the European Medicines ...
The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...
The Orphan Drug designation was supported by preclinical research and preliminary data from the dose escalation/expansion phase 1/2 trial.
Click here for an analysis of Cartesian Therapeutics' recent stock rebound and RNA cell therapy assets, including mixed ...
Binod Dhakal, MD, MS, discusses some of the next steps for evaluating ciltacabtagene autoleucel in multiple myeloma and the CARTITUDE-4 trial.
DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback